Incannex Healthcare Limited
https://incannex.com.au/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Incannex Healthcare Limited
Ozempic Cuts Kidney Risk By 24%
But Novo’s blockbuster lags established drugs in diabetic kidney disease patients, and will probably be regarded as an adjunct.
MTI 100: Global Medtech Recovers Core Growth After A Year Like No Other
With many medtechs restructuring for core growth in the post-pandemic era, Abbott relied on organic growth in 2022 to move to the top of the global medtech ranking. The strength of the US dollar was not kind to companies reporting in local currencies on converting revenues to dollars.
The FLOW Of Novo Nordisk's Semaglutide Success Rolls Into Kidney Disease
The Danish giant’s GLP-1 agonist blockbuster is effective against diabetes, obesity and cardiovascular disease. Now kidney disease can be added to the list after a Phase III trial was halted for efficacy.
News We’re Watching: Abbott FreeStyle Libre Recall, Medtronic Partners With DaVita, Free SBOM Software
This week, Abbott announced a class I recall of several glucose management systems. Additionally, Medtronic announced partnerships with DaVita and Qure.Ai; Heartflow closed a funding round; and BiVacor readies for artificial heart trials.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Mount Magnet South Ltd.
- Gameday International Pty Ltd
- Incannex Pty Ltd
- Impression Healthcare Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice